HeartLung Announces USPTO Issuance of Foundational AI-CVD Patent and Allowance for Vasa Vasorum Inflammation Imaging

New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary ...
The Manila Times

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Ca…

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from ACACIA-HCM (Assessment Comparing ...

Cytokinetics, Incorporated: Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-O…

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...
pharmaphorum

New biotech Atrium born out of Novartis/Avidity marriage

Kathleen Gallagher is chief executive of Atrium, which is developing siRNA therapies for genetic cardiomyopathies. As Novartis completed its $12 billion takeover of Avidity, a new cardiology-focused ...
Frontiers

Left Atrial Appendage Exclusion for Stroke Prevention in Atrial Fibrillation: Surgical, Percutaneous, and Hybrid Approaches

Atrial fibrillation (AF) is becoming more common as populations age and more patients live with multiple conditions. AF remains a major cause of ...
The Cardiology Advisor

Ultra-Low Temperature Ablation Effective for VT in Structural Heart Disease

The FULCRUM-VT trial evaluated the clinical utility of ultra-low temperature ablation for treating ventricular tachycardia in ...